Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer.
Reads0
Chats0
TLDR
Comparing the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast, colorectal, or prostate cancer is compared and the CTC definition used in these studies is reviewed.Abstract:
The increasing number of treatment options for patients with metastatic carcinomas has created a concomitant need for new methods to monitor their use. Ideally, these modalities would be noninvasive, be independent of treatment, and provide quantitative real-time analysis of tumor activity in a variety of carcinomas. Assessment of circulating tumor cells (CTCs) shed into the blood during metastasis may satisfy this need. We developed the CellSearch System to enumerate CTC from 7.5 mL of venous blood. In this review we compare the outcomes from three prospective multicenter studies investigating the use of CTC to monitor patients undergoing treatment for metastatic breast (MBC), colorectal (MCRC), or prostate cancer (MPC) and review the CTC definition used in these studies. Evaluation of CTC at anytime during the course of disease allows assessment of patient prognosis and is predictive of overall survival.read more
Citations
More filters
Journal ArticleDOI
Nanotechnology for enrichment and detection of circulating tumor cells.
TL;DR: This review discusses the CTC enrichment and detection technologies based on a variety of functional nanosystems and nanostructured substrates, with the goal of highlighting the role of nanotechnology in the advancement of basic and clinical CTC research.
Journal ArticleDOI
Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.
Wataru Okajima,Shuhei Komatsu,Daisuke Ichikawa,Mahito Miyamae,Takuma Ohashi,Taisuke Imamura,Jun Kiuchi,Keiji Nishibeppu,Tomohiro Arita,Hirotaka Konishi,Atsushi Shiozaki,Ryo Morimura,Hisashi Ikoma,Kazuma Okamoto,Eigo Otsuji +14 more
TL;DR: Recent developments based on the available literature on both circulating tumor cells and cell-free nucleic acids in cancer patients, especially focusing on Hepatocellular carcinoma are reviewed.
Journal ArticleDOI
Role of the EpCAM (CD326) in prostate cancer metastasis and progression
Jie Ni,Jie Ni,Paul J. Cozzi,Paul J. Cozzi,Wei Duan,Sarah Shigdar,Peter Graham,Peter Graham,Kearsley H. John,Kearsley H. John,Yong Li,Yong Li +11 more
TL;DR: The implications of the newly identified roles of EpCAM in terms of its diagnostic and metastatic relevance to CaP are discussed and emerging and innovative approaches to the management of the disease and expanding potential therapeutic applications ofEpCAM for targeted strategies in future CaP therapy are explored.
Journal ArticleDOI
Multivalent Aptamer Functionalized Ag 2 S Nanodots/Hybrid Cell Membrane-Coated Magnetic Nanobioprobe for the Ultrasensitive Isolation and Detection of Circulating Tumor Cells
TL;DR: A nanoplatform is developed for the efficient isolation and ultrasensitive detection of CTCs by combining near‐infrared (NIR) multivalent aptamer functionalized Ag2S nanodots with hybrid cell membrane‐coated magnetic nanoparticles.
Journal ArticleDOI
Annexin-1-mediated Endothelial Cell Migration and Angiogenesis Are Regulated by Vascular Endothelial Growth Factor (VEGF)-induced Inhibition of miR-196a Expression
Anne Laure Pin,François Houle,Patrick Fournier,Maëva Guillonneau,Eric Paquet,Martin J. Simard,Isabelle Royal,Jacques Huot +7 more
TL;DR: It is concluded that the VEGF-induced decrease of miR-196a expression may participate to the angiogenic switch by maintaining the expression of ANXA1 to levels required to enable p38/MAPKAP kinase-2/LIMK1/annexin-A1-dependent endothelial cell migration and angiogenesis in response to VEGf.
References
More filters
Journal ArticleDOI
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
TL;DR: It is now known that the potential of a tumour cell to metastasize depends on its interactions with the homeostatic factors that promote tumour-cell growth, survival, angiogenesis, invasion and metastasis.
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Sunitha Nagrath,Lecia V. Sequist,Shyamala Maheswaran,Daphne W. Bell,Daphne W. Bell,Daniel Irimia,Lindsey Ulkus,Matthew R. Smith,Eunice L. Kwak,Subba R. Digumarthy,Alona Muzikansky,Paula D. Ryan,Ulysses J. Balis,Ulysses J. Balis,Ronald G. Tompkins,Daniel A. Haber,Mehmet Toner +16 more
TL;DR: The CTC-chip successfully identified CTCs in the peripheral blood of patients with metastatic lung, prostate, pancreatic, breast and colon cancer in 115 of 116 samples, with a range of 5–1,281CTCs per ml and approximately 50% purity.
Journal ArticleDOI
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W. Jeffrey Allard,Jeri Matera,M. Craig Miller,Madeline Repollet,Mark Connelly,Chandra Rao,Arjan G.J. Tibbe,Jonathan W. Uhr,Leon W.M.M. Terstappen +8 more
TL;DR: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.